Review



454 21n  (Carna Inc)


Bioz Verified Symbol Carna Inc is a verified supplier
Bioz Manufacturer Symbol Carna Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Carna Inc 454 21n
    454 21n, supplied by Carna Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/BTN-FLT3/pmc13018901-19-5-2
    Average 93 stars, based on 1 article reviews
    454 21n - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    other:

    Article Title:
    Article Snippet: BTN-FLT3 , Carna Biosciences , 08-454-21N.



    Similar Products

    95
    Miltenyi Biotec 130 096 479 interleukin 3 il 3 r d systems 203 il 010 cf
    130 096 479 Interleukin 3 Il 3 R D Systems 203 Il 010 Cf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Human+Flt3-Ligand%2C+premium+grade/pm43020948-187-388-386
    Average 95 stars, based on 1 article reviews
    130 096 479 interleukin 3 il 3 r d systems 203 il 010 cf - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    Proteintech flt3 ligand
    Flt3 Ligand, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Animal-free+Recombinant+Human+FLT3+Ligand/pm43027380-66-68-71
    Average 93 stars, based on 1 article reviews
    flt3 ligand - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec recombinant murine flt3l
    Recombinant Murine Flt3l, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Mouse+Flt3-Ligand%2C+research+grade/pm42950826-253-64-67
    Average 93 stars, based on 1 article reviews
    recombinant murine flt3l - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec flt3 ligand
    (A) Somatic SV counts per bulk WGS sample, stratified: shared between hg38-based and pangenome-based alignments and unique per alignment category. (B) Ideograms of somatic SV events in the AML bulk sample identified with pangenome-based and hg38-based analyses across deletions (i), translocations (ii), and duplications (iii). Driver SV events are shown in red. (C) Circos plot of the pericentromeric SV cluster at 9p12, initially called as somatic in pangenome-based alignments and subsequently resolved as germline. (D) SequenceTubeMap graph alignment visualization of the pericentromeric SV starting breakend in AML sample long-read data (top, colorful), AML bulk short-read data (middle, red), and MSC control short-read data (bottom, gray) samples for the start (i) and end (ii) breakends of the SV. Red stars mark the exact positions of the breakends. (E) Synteny plot of pairwise alignments of chromosome 9 (hg38 on pangenome and pangenome on T2T-CHM13).
    Flt3 Ligand, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Human+Flt3-Ligand%2C+research+grade/bio_rxiv__64898__2026__10__27__756267-165-24-31
    Average 95 stars, based on 1 article reviews
    flt3 ligand - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress irak4 flt3 inhibitor
    (A) Somatic SV counts per bulk WGS sample, stratified: shared between hg38-based and pangenome-based alignments and unique per alignment category. (B) Ideograms of somatic SV events in the AML bulk sample identified with pangenome-based and hg38-based analyses across deletions (i), translocations (ii), and duplications (iii). Driver SV events are shown in red. (C) Circos plot of the pericentromeric SV cluster at 9p12, initially called as somatic in pangenome-based alignments and subsequently resolved as germline. (D) SequenceTubeMap graph alignment visualization of the pericentromeric SV starting breakend in AML sample long-read data (top, colorful), AML bulk short-read data (middle, red), and MSC control short-read data (bottom, gray) samples for the start (i) and end (ii) breakends of the SV. Red stars mark the exact positions of the breakends. (E) Synteny plot of pairwise alignments of chromosome 9 (hg38 on pangenome and pangenome on T2T-CHM13).
    Irak4 Flt3 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/IRAK4%2C+Human/10__1016_slash_j__jes__2026__105801-55-8-24
    Average 94 stars, based on 1 article reviews
    irak4 flt3 inhibitor - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    91
    TargetMol mertk flt3 kinase inhibitor mrx 2843
    Mertk mediates Bmal1-dependent preservation of macrophage efferocytosis under lipid stress and supports a proposed working model of plaque remodeling. A , B Representative images ( A ) and quantification ( B ) of efferocytosis in BMDMs under untreated control conditions, oxidized low-density lipoprotein (ox-LDL) exposure, ox-LDL plus Bmal1 knockdown, or ox-LDL plus Bmal1 knockdown with Mertk re-expression. C , D Complementary gain-of-function and inhibitor experiment under untreated control conditions, ox-LDL exposure, ox-LDL plus Bmal1 overexpression, or ox-LDL plus Bmal1 overexpression with the <t>Mertk/FLT3</t> kinase <t>inhibitor</t> <t>MRX-2843</t> (150 nM; 2-h pretreatment). Apoptotic Jurkat targets were labeled with CFDA-SE (green), BMDMs with CMTPX (red), and nuclei with DAPI (blue). Scale bar, 50 μm; the bar shown at the lower left of A applies to both A and C. The efferocytosis index was the percentage of red macrophages containing at least one internalized green apoptotic target. For each condition, BMDMs isolated separately from three donor mice were maintained in three donor-specific culture dishes, with each dish constituting one biological replicate ( n = 3). Two completely nonoverlapping fields were acquired from each dish and retained as separate field-level measurements; therefore, six points are shown per condition (two fields nested within each of three biological replicates). Data are mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple-comparison test. All reported experimental-comparison P values are two-sided. *** P < 0.001. E Proposed working model integrating human systems-genetic candidate prioritization with the mouse plaque-remodeling phenotype and macrophage experiments. The functional Bmal1–Mertk dependency was established in cultured macrophages; its contribution to the complete in vivo response to IF remains a proposed link that requires macrophage-specific genetic validation. CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CMTPX, CellTracker Red CMTPX
    Mertk Flt3 Kinase Inhibitor Mrx 2843, supplied by TargetMol, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/MRX-2843/pmc13741550-49-2-9
    Average 91 stars, based on 1 article reviews
    mertk flt3 kinase inhibitor mrx 2843 - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec recombinant human flt3 ligand miltenyi biotec
    Mertk mediates Bmal1-dependent preservation of macrophage efferocytosis under lipid stress and supports a proposed working model of plaque remodeling. A , B Representative images ( A ) and quantification ( B ) of efferocytosis in BMDMs under untreated control conditions, oxidized low-density lipoprotein (ox-LDL) exposure, ox-LDL plus Bmal1 knockdown, or ox-LDL plus Bmal1 knockdown with Mertk re-expression. C , D Complementary gain-of-function and inhibitor experiment under untreated control conditions, ox-LDL exposure, ox-LDL plus Bmal1 overexpression, or ox-LDL plus Bmal1 overexpression with the <t>Mertk/FLT3</t> kinase <t>inhibitor</t> <t>MRX-2843</t> (150 nM; 2-h pretreatment). Apoptotic Jurkat targets were labeled with CFDA-SE (green), BMDMs with CMTPX (red), and nuclei with DAPI (blue). Scale bar, 50 μm; the bar shown at the lower left of A applies to both A and C. The efferocytosis index was the percentage of red macrophages containing at least one internalized green apoptotic target. For each condition, BMDMs isolated separately from three donor mice were maintained in three donor-specific culture dishes, with each dish constituting one biological replicate ( n = 3). Two completely nonoverlapping fields were acquired from each dish and retained as separate field-level measurements; therefore, six points are shown per condition (two fields nested within each of three biological replicates). Data are mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple-comparison test. All reported experimental-comparison P values are two-sided. *** P < 0.001. E Proposed working model integrating human systems-genetic candidate prioritization with the mouse plaque-remodeling phenotype and macrophage experiments. The functional Bmal1–Mertk dependency was established in cultured macrophages; its contribution to the complete in vivo response to IF remains a proposed link that requires macrophage-specific genetic validation. CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CMTPX, CellTracker Red CMTPX
    Recombinant Human Flt3 Ligand Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Human+IL-7%2C+research+grade/pm42486103-554-30-33
    Average 96 stars, based on 1 article reviews
    recombinant human flt3 ligand miltenyi biotec - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec flt3 l
    Mertk mediates Bmal1-dependent preservation of macrophage efferocytosis under lipid stress and supports a proposed working model of plaque remodeling. A , B Representative images ( A ) and quantification ( B ) of efferocytosis in BMDMs under untreated control conditions, oxidized low-density lipoprotein (ox-LDL) exposure, ox-LDL plus Bmal1 knockdown, or ox-LDL plus Bmal1 knockdown with Mertk re-expression. C , D Complementary gain-of-function and inhibitor experiment under untreated control conditions, ox-LDL exposure, ox-LDL plus Bmal1 overexpression, or ox-LDL plus Bmal1 overexpression with the <t>Mertk/FLT3</t> kinase <t>inhibitor</t> <t>MRX-2843</t> (150 nM; 2-h pretreatment). Apoptotic Jurkat targets were labeled with CFDA-SE (green), BMDMs with CMTPX (red), and nuclei with DAPI (blue). Scale bar, 50 μm; the bar shown at the lower left of A applies to both A and C. The efferocytosis index was the percentage of red macrophages containing at least one internalized green apoptotic target. For each condition, BMDMs isolated separately from three donor mice were maintained in three donor-specific culture dishes, with each dish constituting one biological replicate ( n = 3). Two completely nonoverlapping fields were acquired from each dish and retained as separate field-level measurements; therefore, six points are shown per condition (two fields nested within each of three biological replicates). Data are mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple-comparison test. All reported experimental-comparison P values are two-sided. *** P < 0.001. E Proposed working model integrating human systems-genetic candidate prioritization with the mouse plaque-remodeling phenotype and macrophage experiments. The functional Bmal1–Mertk dependency was established in cultured macrophages; its contribution to the complete in vivo response to IF remains a proposed link that requires macrophage-specific genetic validation. CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CMTPX, CellTracker Red CMTPX
    Flt3 L, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Human+Flt3-Ligand%2C+premium+grade/10__1016_slash_j__isci__2026__116736-656-33-34
    Average 95 stars, based on 1 article reviews
    flt3 l - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec human fms like tyrosine kinase ligand hflt3 ligand
    Mertk mediates Bmal1-dependent preservation of macrophage efferocytosis under lipid stress and supports a proposed working model of plaque remodeling. A , B Representative images ( A ) and quantification ( B ) of efferocytosis in BMDMs under untreated control conditions, oxidized low-density lipoprotein (ox-LDL) exposure, ox-LDL plus Bmal1 knockdown, or ox-LDL plus Bmal1 knockdown with Mertk re-expression. C , D Complementary gain-of-function and inhibitor experiment under untreated control conditions, ox-LDL exposure, ox-LDL plus Bmal1 overexpression, or ox-LDL plus Bmal1 overexpression with the <t>Mertk/FLT3</t> kinase <t>inhibitor</t> <t>MRX-2843</t> (150 nM; 2-h pretreatment). Apoptotic Jurkat targets were labeled with CFDA-SE (green), BMDMs with CMTPX (red), and nuclei with DAPI (blue). Scale bar, 50 μm; the bar shown at the lower left of A applies to both A and C. The efferocytosis index was the percentage of red macrophages containing at least one internalized green apoptotic target. For each condition, BMDMs isolated separately from three donor mice were maintained in three donor-specific culture dishes, with each dish constituting one biological replicate ( n = 3). Two completely nonoverlapping fields were acquired from each dish and retained as separate field-level measurements; therefore, six points are shown per condition (two fields nested within each of three biological replicates). Data are mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple-comparison test. All reported experimental-comparison P values are two-sided. *** P < 0.001. E Proposed working model integrating human systems-genetic candidate prioritization with the mouse plaque-remodeling phenotype and macrophage experiments. The functional Bmal1–Mertk dependency was established in cultured macrophages; its contribution to the complete in vivo response to IF remains a proposed link that requires macrophage-specific genetic validation. CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CMTPX, CellTracker Red CMTPX
    Human Fms Like Tyrosine Kinase Ligand Hflt3 Ligand, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/flt3/Human+Flt3-Ligand%2C+premium+grade/bio_rxiv__64898__2026__07__07__736903-359-31-37
    Average 95 stars, based on 1 article reviews
    human fms like tyrosine kinase ligand hflt3 ligand - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Somatic SV counts per bulk WGS sample, stratified: shared between hg38-based and pangenome-based alignments and unique per alignment category. (B) Ideograms of somatic SV events in the AML bulk sample identified with pangenome-based and hg38-based analyses across deletions (i), translocations (ii), and duplications (iii). Driver SV events are shown in red. (C) Circos plot of the pericentromeric SV cluster at 9p12, initially called as somatic in pangenome-based alignments and subsequently resolved as germline. (D) SequenceTubeMap graph alignment visualization of the pericentromeric SV starting breakend in AML sample long-read data (top, colorful), AML bulk short-read data (middle, red), and MSC control short-read data (bottom, gray) samples for the start (i) and end (ii) breakends of the SV. Red stars mark the exact positions of the breakends. (E) Synteny plot of pairwise alignments of chromosome 9 (hg38 on pangenome and pangenome on T2T-CHM13).

    Journal: bioRxiv

    Article Title: Somatic variant detection using an individual-specific pangenome reference: a case study of a pediatric acute myeloid leukemia patient

    doi: 10.64898/2026.10.27.756267

    Figure Lengend Snippet: (A) Somatic SV counts per bulk WGS sample, stratified: shared between hg38-based and pangenome-based alignments and unique per alignment category. (B) Ideograms of somatic SV events in the AML bulk sample identified with pangenome-based and hg38-based analyses across deletions (i), translocations (ii), and duplications (iii). Driver SV events are shown in red. (C) Circos plot of the pericentromeric SV cluster at 9p12, initially called as somatic in pangenome-based alignments and subsequently resolved as germline. (D) SequenceTubeMap graph alignment visualization of the pericentromeric SV starting breakend in AML sample long-read data (top, colorful), AML bulk short-read data (middle, red), and MSC control short-read data (bottom, gray) samples for the start (i) and end (ii) breakends of the SV. Red stars mark the exact positions of the breakends. (E) Synteny plot of pairwise alignments of chromosome 9 (hg38 on pangenome and pangenome on T2T-CHM13).

    Article Snippet: HSPC culture medium consisted of StemSpan SFEM II medium (Cat. No. 09655; Stem Cell Technologies) supplemented with SCF (100 ng/mL, Cat. No. 130-096-692; Miltenyi), FLT3 ligand (100 ng/mL, Cat. No. 130-096-474; Miltenyi), IL-6 (20 ng/mL, Cat. No. 130- 093-929; Miltenyi), IL-3 (10 ng/mL, Cat. No. 130-093-909; Miltenyi), TPO (50 ng/mL, Cat. No. 130-095-745; Miltenyi), UM729 (500 nM, Cat. No. 72332; Stem Cell Technologies) and StemRegenin-1 (750 nM, Cat. No. 72342; Stem Cell Technologies).

    Techniques: Control

    (A) Driver analysis results comparison of hg38-based set of variants (upper panel) and pangenome-based set of variants (lower panel). Cell colors correspond to the mutational type. (B) IGV alignment view of the PRSS1 locus comparing hg38-based (top two tracks) and pangenome-based (bottom two tracks) alignments in bulk AML and MSC control samples. (C) IGV alignment view of indel artifact of graph-based mapping in WT1 gene, bulk AML sample.

    Journal: bioRxiv

    Article Title: Somatic variant detection using an individual-specific pangenome reference: a case study of a pediatric acute myeloid leukemia patient

    doi: 10.64898/2026.10.27.756267

    Figure Lengend Snippet: (A) Driver analysis results comparison of hg38-based set of variants (upper panel) and pangenome-based set of variants (lower panel). Cell colors correspond to the mutational type. (B) IGV alignment view of the PRSS1 locus comparing hg38-based (top two tracks) and pangenome-based (bottom two tracks) alignments in bulk AML and MSC control samples. (C) IGV alignment view of indel artifact of graph-based mapping in WT1 gene, bulk AML sample.

    Article Snippet: HSPC culture medium consisted of StemSpan SFEM II medium (Cat. No. 09655; Stem Cell Technologies) supplemented with SCF (100 ng/mL, Cat. No. 130-096-692; Miltenyi), FLT3 ligand (100 ng/mL, Cat. No. 130-096-474; Miltenyi), IL-6 (20 ng/mL, Cat. No. 130- 093-929; Miltenyi), IL-3 (10 ng/mL, Cat. No. 130-093-909; Miltenyi), TPO (50 ng/mL, Cat. No. 130-095-745; Miltenyi), UM729 (500 nM, Cat. No. 72332; Stem Cell Technologies) and StemRegenin-1 (750 nM, Cat. No. 72342; Stem Cell Technologies).

    Techniques: Analysis, Comparison, Control

    Mertk mediates Bmal1-dependent preservation of macrophage efferocytosis under lipid stress and supports a proposed working model of plaque remodeling. A , B Representative images ( A ) and quantification ( B ) of efferocytosis in BMDMs under untreated control conditions, oxidized low-density lipoprotein (ox-LDL) exposure, ox-LDL plus Bmal1 knockdown, or ox-LDL plus Bmal1 knockdown with Mertk re-expression. C , D Complementary gain-of-function and inhibitor experiment under untreated control conditions, ox-LDL exposure, ox-LDL plus Bmal1 overexpression, or ox-LDL plus Bmal1 overexpression with the Mertk/FLT3 kinase inhibitor MRX-2843 (150 nM; 2-h pretreatment). Apoptotic Jurkat targets were labeled with CFDA-SE (green), BMDMs with CMTPX (red), and nuclei with DAPI (blue). Scale bar, 50 μm; the bar shown at the lower left of A applies to both A and C. The efferocytosis index was the percentage of red macrophages containing at least one internalized green apoptotic target. For each condition, BMDMs isolated separately from three donor mice were maintained in three donor-specific culture dishes, with each dish constituting one biological replicate ( n = 3). Two completely nonoverlapping fields were acquired from each dish and retained as separate field-level measurements; therefore, six points are shown per condition (two fields nested within each of three biological replicates). Data are mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple-comparison test. All reported experimental-comparison P values are two-sided. *** P < 0.001. E Proposed working model integrating human systems-genetic candidate prioritization with the mouse plaque-remodeling phenotype and macrophage experiments. The functional Bmal1–Mertk dependency was established in cultured macrophages; its contribution to the complete in vivo response to IF remains a proposed link that requires macrophage-specific genetic validation. CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CMTPX, CellTracker Red CMTPX

    Journal: Cell Communication and Signaling : CCS

    Article Title: Intermittent fasting promotes plaque regression and activates the BMAL1–MERTK efferocytosis axis

    doi: 10.1186/s12964-026-03140-3

    Figure Lengend Snippet: Mertk mediates Bmal1-dependent preservation of macrophage efferocytosis under lipid stress and supports a proposed working model of plaque remodeling. A , B Representative images ( A ) and quantification ( B ) of efferocytosis in BMDMs under untreated control conditions, oxidized low-density lipoprotein (ox-LDL) exposure, ox-LDL plus Bmal1 knockdown, or ox-LDL plus Bmal1 knockdown with Mertk re-expression. C , D Complementary gain-of-function and inhibitor experiment under untreated control conditions, ox-LDL exposure, ox-LDL plus Bmal1 overexpression, or ox-LDL plus Bmal1 overexpression with the Mertk/FLT3 kinase inhibitor MRX-2843 (150 nM; 2-h pretreatment). Apoptotic Jurkat targets were labeled with CFDA-SE (green), BMDMs with CMTPX (red), and nuclei with DAPI (blue). Scale bar, 50 μm; the bar shown at the lower left of A applies to both A and C. The efferocytosis index was the percentage of red macrophages containing at least one internalized green apoptotic target. For each condition, BMDMs isolated separately from three donor mice were maintained in three donor-specific culture dishes, with each dish constituting one biological replicate ( n = 3). Two completely nonoverlapping fields were acquired from each dish and retained as separate field-level measurements; therefore, six points are shown per condition (two fields nested within each of three biological replicates). Data are mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple-comparison test. All reported experimental-comparison P values are two-sided. *** P < 0.001. E Proposed working model integrating human systems-genetic candidate prioritization with the mouse plaque-remodeling phenotype and macrophage experiments. The functional Bmal1–Mertk dependency was established in cultured macrophages; its contribution to the complete in vivo response to IF remains a proposed link that requires macrophage-specific genetic validation. CFDA-SE, carboxyfluorescein diacetate succinimidyl ester; CMTPX, CellTracker Red CMTPX

    Article Snippet: The dual Mertk/FLT3 kinase inhibitor MRX-2843 (Cat# T16144 ; TargetMol) was used for pharmacological inhibition.

    Techniques: Preserving, Control, Knockdown, Expressing, Over Expression, Labeling, Isolation, Comparison, Functional Assay, Cell Culture, In Vivo, Biomarker Discovery, In Vitro